
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
HCPLive highlights key pediatric gastroenterology updates from NASPGHAN 2025, with continuing coverage to follow.
At the






